Drugs / recombinant deoxyribonuclease
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01478698 | Jan 2016 → May 2022 | — | Sir Charles Gairdner Hospital | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant deoxyribonuclease | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01478698 ↗ |
| Known as | DNase | “recombinant deoxyribonuclease (DNase)” NCT01478698 ↗ |
| Route | Other | “DNase 5mg per dose given intraperitoneally” NCT01478698 ↗ |